Jubilant Ingrevia Limited — Investor Meet, 17-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Ingrevia will participate in the Midcap Conference 2025 in Mumbai. The company reported strong Q2FY26 financials, with Revenue at ₹1,121 Cr (+7% YoY), EBITDA at ₹146 Cr (+8% YoY), and PAT at ₹70 Cr (+18% YoY). H1FY26 saw even higher PAT growth of 34%. Specialty Chemicals remain a key growth driver with 26% EBITDA margins and significant CDMO order book additions, including 10+ new molecules with ₹1200Cr+ peak revenue potential. Management is confident of continued growth fueled by Specialty Chemicals and Nutrition, despite market pricing pressures.